Will Moderna win the vaccine race?

Information is not investment advice

While biotech companies are struggling to find the vaccine, investors make bets who’ll win this race.

Moderna has performed really well and skyrocketed close to 250% higher this year so far. If you had invested in it at the right time, you would have doubled or, in the best case, even tripled your account. Does it still have the potential to the upside? Opinions are divided.

On the one hand, Moderna revealed positive phase-1 results for a COVID-19 vaccine on May 18, what made it one of the most promising candidates in this race. The stock price reached its peak at $86 that day.

On the other hand, vaccine experts raised doubts about the potential effectiveness of the Moderna’s vaccine as the company revealed too little information. That pushed the stock price down to $70. Moreover, so many competitors have appeared, more than 100 already. The main competitor is Pfizer as it uses the same technology as Moderna.

Now everybody’s waiting for the phase-2 results. Follow the news as it can cause price movements. These days the price trades near $70. The retracement line is 73.5. Support levels are 62 and 48.

Consider buying these stocks

Inovio

INO stock has outperformed its competitors in 2020, posting gains over 390%. This is a very reliable company with a long history. It’s famous for its effective treatment to clinic for Ebola in 15 months, nine months for MERS and, six and a half months for Zika. It will release its first tests in June.

Gilead

This biotech company created the first coronavirus treatment that was approved by the government. You’ve probably heard of remdesivir. Clinical trials showed it reduced the recovery time required for some patients. Now the company just donates its medicine to hospitals in a huge amount. The question now is what the price will be when the company starts selling it. Piper Sandler analysts anticipate it may bring up to $2 billion in revenue in 2020. So, this company has a really great potential.

Investors from all over the world focus on biotech stocks now as it’s the great chance to make profit without many efforts. It appears not so often. Don’t miss it!

Similar

17.11.2022 17:56 G20: what did the leaders decide?

The G20 summit took place in Bali, Indonesia, on November 2022…

09.09.2022 18:15 The End of Era: What Might the UK Face Next?

The deafening news shocked the whole world yesterday: the British Queen Elizabeth II died peacefully at the age of 96…

10.06.2022 15:53 Why didn't oil prices calm despite OPEC+ attempts?

After months of pressure from the White House, Saudi Arabia relented and agreed with other OPEC+ members to increase production.

wti - west texas intermediate oil brent

Hold onto your hats, folks! The Japanese yen took a nosedive after the Bank of Japan (BOJ) left its ultra-loose policy settings unchanged, including its closely watched yield curve control (YCC) policy. But wait, there's more! The BOJ also removed its forward guidance, which had previously pledged to keep interest rates at current or lower levels. So, what's the scoop? Market expectations had been subdued going into the meeting, but some were still hoping for tweaks to the forward guidance to prepare for an eventual exit from the bank's massive stimulus

fundamental analysis market forecast jpy - japanese yen technical analysis usd forex signals aud - australian dollar

Choose your payment system

Phone number

Select the best time for us to call you.

Select the best time for us to call you. We give calls from Monday to Friday in suggested intervals. In case we couldn't get through, we will try again at the same time the next day. For getting real-time assistance, use FBS chat.